Stock Track | iRhythm Technologies Plunges Nearly 10% as Regulatory Issues Overshadow Growth

Stock Track10-31

Shares of iRhythm Technologies Inc. (NASDAQ: IRTC) plummeted nearly 10% in pre-market trading on Wednesday, following the company's third-quarter earnings report that highlighted ongoing regulatory challenges and higher-than-expected losses, despite strong revenue growth.

The medical technology company reported revenue of $147.5 million for the quarter, representing an 18.4% year-over-year increase. However, the adjusted net loss widened to $39.2 million, or $1 per share, missing analyst estimates. The company attributed the larger losses to increased legal and consulting fees related to FDA remediation efforts and a DOJ subpoena.

Perhaps more concerning for investors was the news that iRhythm had voluntarily delayed regulatory submissions for its anticipated ZCT system, pushing the expected filing to the third quarter of 2025. The delay was prompted by the company's desire to address potential FDA questions, following a warning letter in 2023 and recent 483 observations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198446974?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198446974","market":"hk","top_or_hot":-1,"title":"Stock Track | iRhythm Technologies Plunges Nearly 10% as Regulatory Issues Overshadow Growth","media":"Stock Track","content":"<p>Shares of iRhythm Technologies Inc. (NASDAQ: IRTC) plummeted nearly 10% in pre-market trading on Wednesday, following the company's third-quarter earnings report that highlighted ongoing regulatory challenges and higher-than-expected losses, despite strong revenue growth.</p>\n\n<p>The medical technology company reported revenue of $147.5 million for the quarter, representing an 18.4% year-over-year increase. However, the adjusted net loss widened to $39.2 million, or $1 per share, missing analyst estimates. The company attributed the larger losses to increased legal and consulting fees related to FDA remediation efforts and a DOJ subpoena.</p>\n\n<p>Perhaps more concerning for investors was the news that iRhythm had voluntarily delayed regulatory submissions for its anticipated ZCT system, pushing the expected filing to the third quarter of 2025. The delay was prompted by the company's desire to address potential FDA questions, following a warning letter in 2023 and recent 483 observations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | iRhythm Technologies Plunges Nearly 10% as Regulatory Issues Overshadow Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | iRhythm Technologies Plunges Nearly 10% as Regulatory Issues Overshadow Growth\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-31 20:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of iRhythm Technologies Inc. (NASDAQ: IRTC) plummeted nearly 10% in pre-market trading on Wednesday, following the company's third-quarter earnings report that highlighted ongoing regulatory ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRTC","symbol_name":"Irhythm Technologies Inc.","start_time":0,"source_url":"","article_id":"1198446974","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198446974","pubTimestamp":1730376267,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of iRhythm Technologies Inc.  plummeted nearly 10% in pre-market trading on Wednesday, following the company's third-quarter earnings report that highlighted ongoing regulatory challenges and higher-than-expected losses, despite strong revenue growth.The medical technology company reported revenue of $147.5 million for the quarter, representing an 18.4% year-over-year increase. However, the adjusted net loss widened to $39.2 million, or $1 per share, missing analyst estimates. The company","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRTC":"Irhythm Technologies Inc."},"translate_title":"由于监管问题掩盖了增长，iRhythm Technologies股价暴跌近10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRTC":1},"content_text":"Shares of iRhythm Technologies Inc. (NASDAQ: IRTC) plummeted nearly 10% in pre-market trading on Wednesday, following the company's third-quarter earnings report that highlighted ongoing regulatory challenges and higher-than-expected losses, despite strong revenue growth.\nThe medical technology company reported revenue of $147.5 million for the quarter, representing an 18.4% year-over-year increase. However, the adjusted net loss widened to $39.2 million, or $1 per share, missing analyst estimates. The company attributed the larger losses to increased legal and consulting fees related to FDA remediation efforts and a DOJ subpoena.\nPerhaps more concerning for investors was the news that iRhythm had voluntarily delayed regulatory submissions for its anticipated ZCT system, pushing the expected filing to the third quarter of 2025. The delay was prompted by the company's desire to address potential FDA questions, following a warning letter in 2023 and recent 483 observations.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198446974"}